The Lawyer’s new China Elite report contains the most detailed research available on the PRC legal market and contains unparalleled insight into the country's leading law firms. They vary in size, practice focus and geographic coverage, but they all share one common quality – ambition... Read more
This year, The Lawyer’s annual ranking of the largest UK law firms by turnover is available as an interactive, digital benchmarking tool. For the first time this will allow you to manipulate each data set against the metrics of your choice.
Cambridge Antibody Technology’s (CAT) general counsel Diane Mellett had a spectacularly busy 2004 handling the work relating to CAT’s major litigation against pharmaceutical giant Abbott Laboratories.
The contractual dispute centred on claims by CAT that Abbott had underpaid the royalties it owes to CAT for developing a rheumatoid arthritis drug. After months of preparation the case was heard before the High Court last December after the parties failed to resolve the dispute by mediation. On 20 December, Mr Justice Laddie handed Mellett an early Christmas present by ruling in CAT’s favour.
In addition, CAT’s sole in-house lawyer spent much of the second half of 2004 advising the company on its joint venture with AstraZeneca, which bought up 20 per cent of CAT’s shares.
Mellett has also been preparing CAT’s response to the Myners report on pre-emption rights. The Government-commissioned report, which was prepared by Marks & Spencer chairman Paul Myners, concluded that pre-emption rights are critical to the relationship between the company and its shareholders, but questions whether they have become too inflexible.